News | June 28, 2007

Debris Released During Procedure May Harm Kidney Function

June 29, 2007 - Investigators from the Wake Forest University (WFU) School of Medicine in Winston-Salem N.C. and University of California at San Francisco report that debris liberated during angioplasty and stenting of the kidney arteries may harm kidney function.
Matthew Edwards, M.D., lead researcher and vascular and endovascular surgeon at WFU School of Medicine, said blood was collected from kidney arteries immediately after the performance of an angioplasty and stent procedure in 28 patients. The procedures were performed with distal embolic protection using a commercially available temporary balloon occlusion and aspiration catheter system. Details of this research are published in the July Journal of Vascular Surgery. “Blood analysis revealed thousands of particles (average of more than 2,000 per procedure) which were large enough to block the small blood vessels in the kidney,” said Dr. Edwards. “These increasing amounts of debris collected were directly related to worse kidney function following the procedures.”
Angiograms, demographics and laboratory data were reviewed and the filtration rate was estimated before each procedure as well as four to eight weeks post-operative. Significant associations were observed between procedural and anatomic factors, and the amount of captured debris, including renal stent size, preoperative aspirin use, predilation and the ratio of renal artery stent diameter to artery diameter.
“Blockages of the kidney arteries affect up to 3.5 million Americans age 65 years and older and are an increasingly recognized cause of severe high blood pressure and kidney failure,” added Dr. Edwards. “Treating blockages with surgery, or angioplasty and stenting, to try and improve blood pressure control and kidney function as well as subsequent survival while reducing debris particles is essential, so the patient can be free from heart attacks, strokes and dialysis.”
Dr. Edwards added that further investigation is warranted to establish relationships between atheroembolism, end organ functional impairment and clinical responses. “Our results provide unique insight into the complications of renal artery stenting and guidance so we may move forward with important research designed to improve treatments for this increasingly common disease. Embolic protection devices now exist that may prevent the passage of this debris into the kidney and lead to better patient outcomes.”

For more information: www.VascularWeb.org

Related Content

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Overlay Init